Original articles
Lu Liang, Jijun Fu, Siran Wang, Huiyu Cen, Lingmin Zhang, Safur Rehman Mandukhail, Lingran Du, Qianni Wu, Peiquan Zhang, Xiyong Yu. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1[J]. Acta Pharmaceutica Sinica B, 2020, 10(6): 1036-1046

MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1
Lu Lianga, Jijun Fua, Siran Wangb, Huiyu Cena, Lingmin Zhanga, Safur Rehman Mandukhaila, Lingran Dua, Qianni Wua, Peiquan Zhanga, Xiyong Yua
a Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China;
b Department of Prosthodontics, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China
MiR-142-3p has been reported to act as a tumor suppressor in breast cancer. However, the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown. Here, we found that miR-142-3p was significantly downregulated in the doxorubicin (DOX)-resistant MCF-7 cell line (MCF-7/DOX). MiR-142-3p overexpression increased DOX sensitivity and enhanced DOXinduced apoptosis in breast cancer cells. High-mobility group box 1 (HMGB1) is a direct functional target of miR-142-3p in breast cancer cells and miR-142-3p negatively regulated HMGB1 expression. Moreover, overexpression of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by miR-142-3p up-regulation. In conclusion, miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HMGB1. The miR-142-3p/HMGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients.
Key words:    Breast cancer    MCF-7 cell line    HMGB1    MiR-142-3p    Drug resistance    Chemosensitivity   
Received: 2019-07-24     Revised: 2019-09-03
DOI: 10.1016/j.apsb.2019.11.009
Funds: The authors gratefully acknowledge the financial support by National Natural Science Foundation of China (Nos. 81330007 and U1601227), the Science and Technology Programs of Guangdong Province (Nos. 2014A050503047 and 2015B020225006, China), National Natural Science Foundation of China (81700382).
Corresponding author: Peiquan Zhang, Xiyong Yu     Email:pqzhang@gzhmu.edu.cn;yuxycn@aliyun.com
Author description:
PDF(KB) Free
Lu Liang
Jijun Fu
Siran Wang
Huiyu Cen
Lingmin Zhang
Safur Rehman Mandukhail
Lingran Du
Qianni Wu
Peiquan Zhang
Xiyong Yu

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Shioi Y, Kashiwaba M, Inaba T, Komatsu H, Sugai T, Wakabayashi G. Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor. Am J Case Rep 2014;15:85-9.
3. Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When and how do I use neoadjuvant chemotherapy for breast cancer? Curr Treat Options Oncol 2014;15:86-98.
4. Sharifi S, Barar J, Hejazi MS, Samadi N. Doxorubicin changes Bax/Bcl-xL ratio, Caspase-8 and 9 in breast cancer cells. Adv Pharmaceut Bull 2015;5:351-9.
5. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
6. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer:therapeutic implications. Mol Cancer Ther 2011;10:1533-41.
7. Buyuklu M, Kandemir FM, Ozkaraca M, Set T, Bakirci EM, Topal E. Protective effect of curcumin against contrast induced nephropathy in rat kidney:what is happening to oxidative stress, inflammation, autophagy and apoptosis?. Eur Rev Med Pharmacol Sci 2014;18:461-70.
8. Chang Y, Yan W, He X, Zhang L, Li C, Huang H, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012;143:177-87.
9. McAlpine F, Williamson LE, Tooze SA, Chan EY. Regulation of nutrient-sensitive autophagy by uncoordinated 51-like kinases 1 and 2. Autophagy 2013;9:361-73.
10. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 2013;145:1133-43.
11. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012;8:200-12.
12. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A 2012;109:8253-8.
13. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget 2014;5:7013-26.
14. Sun Q, Liu T, Yuan Y, Guo Z, Xie G, Du S, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer 2015;136:1003-12.
15. Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation:shared themes amid diversity. Nat Rev Genet 2008;9:831-42.
16. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122:6-7.
17. Chen MJ, Wu DW, Wang GC, Wang YC, Chen CY, Lee H. MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Oncotarget 2018;9:13758-67.
18. Sun FD, Wang PC, Luan RL, Zou SH, Du X. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. Eur Rev Med Pharmacol Sci 2018;22:1342-50.
19. Min A, Zhu C, Peng S, Rajthala S, Costea DE, Sapkota D. MicroRNAs as important players and biomarkers in oral carcinogenesis. BioMed Res Int 2015;2015:186904.
20. Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang H, et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (TALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways. Leukemia 2012;26:769-77.
21. Chen HH, Huang WT, Yang LW, Lin CW. The PTEN-AKTmTOR/RICTOR pathway in nasal natural killer cell lymphoma is activated by miR-494-3p via PTEN but inhibited by miR-142-3p via RICTOR. Am J Pathol 2015;185:1487-99.
22. Wu L, Cai C, Wang X, Liu M, Li X, Tang H. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett 2011;585:1322-30.
23. MacKenzie TN, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, et al. Triptolide induces the expression of miR-142-3p:a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther 2013;12:1266-75.
24. Chiou GY, Chien CS, Wang ML, Chen MT, Yang YP, Yu YL, et al. Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. Mol Cell 2013;52:693-706.
25. Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL, et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012;119:4992-5004.
26. Gruber HE, Hoelscher GL, Bethea S, Ingram J, Cox M, Hanley Jr EN. High-mobility group box-1 gene, a potent proin-lammatory mediators, is upregulated in more degenerated human discs in vivo and its receptor upregulated by TNF-a exposure in vitro. Exp Mol Pathol 2015; 98:427-30.
27. Chen M, Liu Y, Varley P, Chang Y, He XX, Huang H, et al. Highmobility group box-1 promotes hepatocellular carcinoma progression through miR-21-mediated matrix metalloproteinase activity. Cancer Res 2015;75:1645-56.
28. Amornsupak K, Insawang T, Thuwajit P, O-Charoenrat P, Eccles SA, Thuwajit C. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Canc 2014;14:955.
29. Ke S, Zhou F, Yang H, Wei Y, Gong J, Mei Z, et al. Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J Oncol 2015;46:1051-8.
30. Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010;126:2-10.
31. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2012;81:103-22.
32. O'Bryan S, Dong S, Mathis JM, Alahari SK. The roles of oncogenic miRNAs and their therapeutic importance in breast cancer. Eur J Cancer 2017;72:1-11.
33. Zou J, Kuang W, Hu J, Rao H. miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZbinding kinase. Biochem Biophys Res Commun 2017;488:247-52.
34. Lee JW, Guan W, Han S, Hong DK, Kim LS, Kim H. MiR-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Sci 2018;109:1404-13.
35. Lu X, Ma J, Chu J, Shao Q, Zhang Y, Lu G, et al. MiR-129-5p sensitizes the response of Her-2 positive breast cancer to trastuzumab by reducing Rps6. Cell Physiol Biochem 2017;44:2346-56.
36. Yang YQ, Qi J, Xu JQ, Hao P. MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN. Tumour Biol 2014;35:10287-93.
37. Xiao P, Liu WL. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Clin Exp Pathol 2015;8:10800-7.
38. Wang Y, Ouyang M, Wang Q, Jian Z. MicroRNA-142-3p inhibits hypoxia/reoxygenation-induced apoptosis and fibrosis of cardiomyocytes by targeting high mobility group box 1. Int J Mol Med 2016;38:1377-86.
39. Wang X, Guo Y, Wang C, Yu H, Yu X, Yu H. MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. Inflammation 2016;39:1718-28.
40. Wild CA, Brandau S, Lotfi R, Mattheis S, Gu X, Lang S, et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 2012;48:409-16.
41. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216:167-75.
42. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, ThodeHalle B, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res 2001;21:3881-5.
43. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, et al. DAMP-mediated autophagy contributes to drug resistance. Autophagy 2011;7:112-4.
44. Mizushima N, Komatsu M. Autophagy:renovation of cells and tissues. Cell 2011;147:728-41.
45. Chaachouay H, Ohneseit P, Toulany M, Kehlbach R, Multhoff G, Rodemann HP. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol 2011;99:287-92.
46. Zhang Y, Liu Y, Xu X. Upregulation of miR-142-3p improves drug sensitivity of acute myelogenous leukemia through reducing P-glycoprotein and repressing autophagy by targeting HMGB1. Transl Oncol 2017;10:410-8.
Similar articles: